US009283239B2

(12) **United States Patent**
**Tabuteau**

(10) **Patent No.: US 9,283,239 B2**
(45) **Date of Patent: *Mar. 15, 2016**

(54) **COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME**

(71) Applicant: **Antecip Bioventures II LLC**, New York, NY (US)

(72) Inventor: **Herriot Tabuteau**, New York, NY (US)

(73) Assignee: **ANTECIP BIOVENTURES II LLC**, New York, NY (US)

( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/635,857**

(22) Filed: **Mar. 2, 2015**

(65) **Prior Publication Data**

US 2015/0164929 A1 Jun. 18, 2015

**Related U.S. Application Data**

(63) Continuation of application No. 14/279,232, filed on May 15, 2014, which is a continuation of application No. 14/063,979, filed on Oct. 25, 2013, now Pat. No. 8,802,658, which is a continuation-in-part of application No. 13/894,274, filed on May 14, 2013.

(60) Provisional application No. 61/646,538, filed on May 14, 2012, provisional application No. 61/647,478, filed on May 15, 2012, provisional application No. 61/654,292, filed on Jun. 1, 2012, provisional application No. 61/654,383, filed on Jun. 1, 2012, provisional application No. 61/655,527, filed on Jun. 5, 2012, provisional application No. 61/655,541, filed on Jun. 5, 2012, provisional application No. 61/764,563, filed on Feb. 14, 2013, provisional application No. 61/762,225, filed on Feb. 7, 2013, provisional application No. 61/767,647, filed on Feb. 21, 2013, provisional application No. 61/767,676, filed on Feb. 21, 2013, provisional application No. 61/803,721, filed on Mar. 20, 2013.

(51) **Int. Cl.**

| | |
|---|---|
| ***A61K 31/675*** | (2006.01) |
| ***A61K 9/20*** | (2006.01) |
| ***A61K 9/00*** | (2006.01) |
| ***A61K 9/28*** | (2006.01) |

(52) **U.S. Cl.**

CPC ..... ***A61K 31/675*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 9/20*** (2013.01); ***A61K 9/2004*** (2013.01); ***A61K 9/28*** (2013.01)

(58) **Field of Classification Search**

CPC ..... A61K 31/675; A61K 9/20; A61K 9/28; A61K 9/0053; A61K 9/2004

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| 4,939,130 | A | 7/1990 | Jaeggi et al. |
| 5,869,471 | A | 2/1999 | Hovancik et al. |
| 6,015,801 | A | 1/2000 | Daifotis |
| 6,419,955 | B1 | 7/2002 | Gabel et al. |
| 6,943,155 | B2 | 9/2005 | Lichtenberger |
| 7,658,939 | B2 | 2/2010 | Oshlack et al. |
| 7,704,977 | B2 | 4/2010 | Leonard |
| 8,053,429 | B2 | 11/2011 | Cumming et al. |
| 8,119,159 | B2 | 2/2012 | Cumming et al. |
| 8,323,689 | B2 | 12/2012 | Cumming et al. |
| 8,323,690 | B2 | 12/2012 | Cumming et al. |
| 8,399,023 | B2 | 3/2013 | Hanna et al. |
| 8,772,267 | B2 | 7/2014 | Pappagallo |
| 8,828,431 | B2 | 9/2014 | Cumming et al. |
| 8,859,530 | B2 | 10/2014 | Desai |
| 8,865,757 | B1 | 10/2014 | Tabuteau |
| 8,883,201 | B2 | 11/2014 | Leonard |
| 8,883,203 | B2 | 11/2014 | Leonard |
| 8,901,161 | B1 | 12/2014 | Tabuteau |
| 8,901,162 | B1 | 12/2014 | Tabuteau |
| 8,933,057 | B2 | 1/2015 | Hanna et al. |
| 2004/0063670 | A1 | 4/2004 | Fox et al. |
| 2009/0281064 | A1 | 11/2009 | Ahmed et al. |
| 2010/0215743 | A1 | 8/2010 | Leonard |
| 2011/0028435 | A1 | 2/2011 | Hanna et al. |

(Continued)

FOREIGN PATENT DOCUMENTS

| | | |
|---|---|---|
| CN | 101259133 | 3/2008 |
| WO | 02087555 | 11/2002 |

(Continued)

OTHER PUBLICATIONS

Yasuhisa Abe, Kousuke Iba, Junichi Takada, Takuro Wada, Toshihiko Yamashita, Improvement of Pain and Regional Osteoporotic Changes in the Foot and Ankle by Low-dose Bisphosphonate Therapy for Complex Regional Pain Syndrome Type I, J Med Case Reports. 2011;5(349).*

Package insert for Fosamax, Aug. 2015.*

Package insert for Actonel, Jul. 2009.*

Serge Cremers, Socrates Papapoulos, Pharmacology of bisphosphonates, Bone 49 (2011) 42-49.*

U.S. Appl. No. 14/495,732, filed Jan. 26, 2015 First Named Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.

U.S. Appl. No. 14/481,097, filed Sep. 9, 2014 First Named Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.

U.S. Appl. No. 14/538,709, filed Nov. 11, 2014 First Named Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.

U.S. Appl. No. 14/530,556, filed Oct. 31, 2014 First Named Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.

U.S. Appl. No. 14/536,526, filed Jan. 28, 2015 First Named Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.

(Continued)

*Primary Examiner* — Sarah Pihonak
*Assistant Examiner* — Jason A Deck
(74) *Attorney, Agent, or Firm* — K&L Gates LLP; Louis C. Cullman; Brent A. Johnson

(57) **ABSTRACT**

Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.

**17 Claims, 10 Drawing Sheets**